The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radioligand Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Actinium 225 (Ac-225)
1.2.3 Lutetium 177 (Lu-177)
1.2.4 Gallium 68 (Ga-68)
1.2.5 Fluorine 18 (F-18)
1.2.6 Other Radionuclides
1.3 Market by Application
1.3.1 Global Radioligand Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Neuroendocrine Neoplasms
1.3.3 Prostate Cancer
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radioligand Therapy Market Perspective (2018-2029)
2.2 Radioligand Therapy Growth Trends by Region
2.2.1 Global Radioligand Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Radioligand Therapy Historic Market Size by Region (2018-2023)
2.2.3 Radioligand Therapy Forecasted Market Size by Region (2024-2029)
2.3 Radioligand Therapy Market Dynamics
2.3.1 Radioligand Therapy Industry Trends
2.3.2 Radioligand Therapy Market Drivers
2.3.3 Radioligand Therapy Market Challenges
2.3.4 Radioligand Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radioligand Therapy Players by Revenue
3.1.1 Global Top Radioligand Therapy Players by Revenue (2018-2023)
3.1.2 Global Radioligand Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Radioligand Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radioligand Therapy Revenue
3.4 Global Radioligand Therapy Market Concentration Ratio
3.4.1 Global Radioligand Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioligand Therapy Revenue in 2022
3.5 Radioligand Therapy Key Players Head office and Area Served
3.6 Key Players Radioligand Therapy Product Solution and Service
3.7 Date of Enter into Radioligand Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioligand Therapy Breakdown Data by Type
4.1 Global Radioligand Therapy Historic Market Size by Type (2018-2023)
4.2 Global Radioligand Therapy Forecasted Market Size by Type (2024-2029)
5 Radioligand Therapy Breakdown Data by Application
5.1 Global Radioligand Therapy Historic Market Size by Application (2018-2023)
5.2 Global Radioligand Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Radioligand Therapy Market Size (2018-2029)
6.2 North America Radioligand Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Radioligand Therapy Market Size by Country (2018-2023)
6.4 North America Radioligand Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radioligand Therapy Market Size (2018-2029)
7.2 Europe Radioligand Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Radioligand Therapy Market Size by Country (2018-2023)
7.4 Europe Radioligand Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radioligand Therapy Market Size (2018-2029)
8.2 Asia-Pacific Radioligand Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Radioligand Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Radioligand Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radioligand Therapy Market Size (2018-2029)
9.2 Latin America Radioligand Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Radioligand Therapy Market Size by Country (2018-2023)
9.4 Latin America Radioligand Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radioligand Therapy Market Size (2018-2029)
10.2 Middle East & Africa Radioligand Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Radioligand Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Radioligand Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Radioligand Therapy Introduction
11.1.4 Novartis Revenue in Radioligand Therapy Business (2018-2023)
11.1.5 Novartis Recent Development
11.2 Advanced Accelerator Applications
11.2.1 Advanced Accelerator Applications Company Detail
11.2.2 Advanced Accelerator Applications Business Overview
11.2.3 Advanced Accelerator Applications Radioligand Therapy Introduction
11.2.4 Advanced Accelerator Applications Revenue in Radioligand Therapy Business (2018-2023)
11.2.5 Advanced Accelerator Applications Recent Development
11.3 Mercy Radiology
11.3.1 Mercy Radiology Company Detail
11.3.2 Mercy Radiology Business Overview
11.3.3 Mercy Radiology Radioligand Therapy Introduction
11.3.4 Mercy Radiology Revenue in Radioligand Therapy Business (2018-2023)
11.3.5 Mercy Radiology Recent Development
11.4 POINT Biopharma Global Inc
11.4.1 POINT Biopharma Global Inc Company Detail
11.4.2 POINT Biopharma Global Inc Business Overview
11.4.3 POINT Biopharma Global Inc Radioligand Therapy Introduction
11.4.4 POINT Biopharma Global Inc Revenue in Radioligand Therapy Business (2018-2023)
11.4.5 POINT Biopharma Global Inc Recent Development
11.5 Fusion Pharma
11.5.1 Fusion Pharma Company Detail
11.5.2 Fusion Pharma Business Overview
11.5.3 Fusion Pharma Radioligand Therapy Introduction
11.5.4 Fusion Pharma Revenue in Radioligand Therapy Business (2018-2023)
11.5.5 Fusion Pharma Recent Development
11.6 Telix Pharmaceuticals Ltd
11.6.1 Telix Pharmaceuticals Ltd Company Detail
11.6.2 Telix Pharmaceuticals Ltd Business Overview
11.6.3 Telix Pharmaceuticals Ltd Radioligand Therapy Introduction
11.6.4 Telix Pharmaceuticals Ltd Revenue in Radioligand Therapy Business (2018-2023)
11.6.5 Telix Pharmaceuticals Ltd Recent Development
11.7 Lantheus Holdings, Inc
11.7.1 Lantheus Holdings, Inc Company Detail
11.7.2 Lantheus Holdings, Inc Business Overview
11.7.3 Lantheus Holdings, Inc Radioligand Therapy Introduction
11.7.4 Lantheus Holdings, Inc Revenue in Radioligand Therapy Business (2018-2023)
11.7.5 Lantheus Holdings, Inc Recent Development
11.8 Bayer AG
11.8.1 Bayer AG Company Detail
11.8.2 Bayer AG Business Overview
11.8.3 Bayer AG Radioligand Therapy Introduction
11.8.4 Bayer AG Revenue in Radioligand Therapy Business (2018-2023)
11.8.5 Bayer AG Recent Development
11.9 Curium Pharma
11.9.1 Curium Pharma Company Detail
11.9.2 Curium Pharma Business Overview
11.9.3 Curium Pharma Radioligand Therapy Introduction
11.9.4 Curium Pharma Revenue in Radioligand Therapy Business (2018-2023)
11.9.5 Curium Pharma Recent Development
11.10 Precirix
11.10.1 Precirix Company Detail
11.10.2 Precirix Business Overview
11.10.3 Precirix Radioligand Therapy Introduction
11.10.4 Precirix Revenue in Radioligand Therapy Business (2018-2023)
11.10.5 Precirix Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details